Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary

Suzuki, Kayo; Takakura, Satoshi; Saito, Motoaki; Morikawa, Akio; Suzuki, Jun; Takahashi, Kazuaki; Nagata, Chie; Yanaihara, Nozomu; Tanabe, Hiroshi; Okamoto, Aikou

doi:10.1097/igc.0000000000000178

Cited by 17 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with clear cell carcinoma are typically young and are often diagnosed with stage I–II disease. Therefore, they do not exhibit poor prognosis [ 21 ]. In the present study, the majority of clear cell carcinoma cases presented as stage I or II (46 out of 60 cases) with a 5-year overall survival rate of approximately 80%.…”

Section: Discussionmentioning

confidence: 99%

“…Human 3×FLAG-tagged full-length MCM2 ( 3 × FLAG-MCM2-FL ) and 3×FLAG-tagged N-terminal-deficient MCM2 ( 3 × FLAG-MCM2- ΔN) were subcloned using the cDNA from HEK293T cells. PCR primers for MCM2-FL used in this study have been previously described [ 21 ]. The PCR primers for MCM2-ΔN were as follows: forward primer: 5′-AATATGCGGCCGCGCG GGCCACGGAGGACGGCG-3′ and reverse primer: 5′-AGCGGCCGCAAGCAGGCTTGGAGAAACAA-3′.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis. In this study, we showed that MCM2 is highly expressed in clinical samples of ovarian clear cell carcinoma. Although MCM2 expression was mainly localized to the nuclei as in other cancers, a few cases exhibited cytoplasmic localization of MCM2. Surprisingly, tumor samples with cytoplasmic MCM2 demonstrated excellent prognosis, showing 100% survival during the observation period of more than 200 months. However, cases with nuclear expression of MCM2 exhibited approximately 78% 5-year-survival rate. In a previous study, we showed that Friend leukemia virus (FLV) envelope protein gp70 bound to MCM2, impaired its nuclear translocation, and enhanced DNA damage-induced apoptosis in FLV-infected hematopoietic cells with high levels of MCM2. As expected, clear cell carcinoma cells with cytoplasmic expression of MCM2 exhibited significantly higher apoptotic cell ratio than that of cells with nuclear MCM2 expression. In vitro experiments using ovarian cancer cells with cytoplasmic expression of MCM2 demonstrated that transfection of MCM2-ΔN enhanced DNA damage-induced apoptosis. Therefore, cytoplasmic localization of MCM2 significantly correlated with increased apoptosis in clear cell carcinoma cells, resulting in improved prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…According to the current retrospective literature, the necessity of systemic lymph node dissection in patients with OCCC is still controversial. Suzuk et al [20] demonstrated that signi cant differences were observed in progression-free survival and overall survival between patients optimally and nonoptimally staged with stages IA/IC1 OCCC, but no signi cant difference was found in those with stages IC2/IC3. Surgical staging category was the only independent prognostic factor for recurrence-free survival in stages IA/IC1 OCCC.…”

Section: Discussionmentioning

confidence: 99%

Age and Lymph Nodes Examination May Be Related to the Outcome of Ovarian Clear Cell Carcinoma: A SEER Analysis

Zhu

Jia

Jiang

2021

Preprint

View full text Add to dashboard Cite

AimTo analyze and compare the demographics, treatment, and survival rates in patients with ovarian clear cell carcinoma (OCCC).MethodsWe conducted a population-based retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1998 to 2016. Data of 4344 women with OCCC were compared, and survival was analyzed using the Kaplan–Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model.ResultsThere was no significant difference in cause specific survival (CSS) regardless of chemotherapy in stage I and stage II OCCC. In women with stage III/IV OCCC, there was an increased mortality in women without chemotherapy (5-year CSS 29.80% vs. 24.90%, p<0.001). Among stage I women younger than 60 years old, the 5-year CSS of those underwent chemotherapy was worse than that of non-chemotherapy (86.4% vs. 97.50%, p=0.002). Among these patients, omitting chemotherapy had improved CSS (HR 0.539; 95% CI 0.386-0.753), and omitting lymph nodes examination had decreased CSS (HR 1.666; 95% CI 1.230-2.256). In stage III/IV women who were 60 years or older, the 5-year CSS of those underwent chemotherapy was better than that of non-chemotherapy (32.60% vs. 24.30%, p<0.001). Among these patients, omitting chemotherapy (HR 1.769; 95% CI 1.385-2.258) and omitting lymph nodes examination (HR 1.709; 95% CI 1.371-2.130) had lower CSS.ConclusionChemotherapy has different effects in patients with OCCC at different stages and ages. Age and lymph nodes examination may be factors that affect the outcome of patients with OCCC.

show abstract

“…Nowadays, it is considered that optimal surgical cytoreduction can be defined only if there are no macroscopically visible remains. The aim of cytoreductive surgery is to enhance the effects of cytostatics on possible residual tumor cells [12,13]. When planning the treatment of ovarian cancers, special circumstances and situations must be considered: sparing surgery which preserves woman's fertility, surgery of ovarian cancer with low malignant potential (borderline tumors), surgical treatment of epithelial and germ cell ovarian cancer adjusted to different FIGO stages, use of laparoscopic technique and surgical treatment of ovarian cancer in pregnancy [2].…”

Section: Discussionmentioning

confidence: 99%

“…Only a well trained surgical team can perform all necessary interventions on different abdominal organs, including large and small bowel, liver, spleen, lymph nodes, diaphragm etc. and be a reliable "prognostic factor" in ovarian cancer surgical treatment [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

Novel diagnostic and therapeutic approaches to the treatment of ovarian cancer

Djurdjevic¹,

Stojanović²,

Basta-Nikolić³

et al. 2019

Med pregl

View full text Add to dashboard Cite

Introduction. Ovarian cancer is an intra-abdominal, chemosensitive, chronic disease and according to current protocols, it is primarily treated with surgery followed by adjuvant chemotherapy. In Serbia, 820 cases of ovarian cancer are newly diagnosed annually. The aim of the study is to present the results of surgical treatment in 304 patients with ovarian cancer, treated during a 15-year period (2003-2017) at the Clinic of Gynecology and Obstetrics, Clinical Center of Vojvodina in Novi Sad. Material and Methods. Before the operation, clinical, gynecological, ultrasonography examination and analysis of cancer antigen 125 blood concentrations were performed in all patients. Based on basic diagnostics, additional pelvic, abdominal and thoracic computed tomography or magnetic resonance imaging studies, together with colonoscopy if needed, were performed. The selection of the type and extent of surgical procedure was based on intraoperative assessment of the stage of disease, intraoperative histopathological confirmation of ovarian cancer, wish for fertility preservation and general patient's condition. Exclusion criteria were histopathologically confirmed benign or borderline ovarian tumors, i. e. absence of cancer in the final microscopic specimen. Results. The patients' age ranged from 19-88 years, with a median of 53.4 years. According to the International Fede-International Federation of Gynecology and Obstetrics staging, most patients had stage III-98 (33.1%) and epithelial ovarian cancer-240 (84.2%). The most common surgical procedures were hysterectomy with bilateral adnexectomy and omentectomy, whereas cytological analysis was performed in 138 (45.4%) treated patients. Complications were recorded in 13 (4.3%) operated patients with inflammation and wound seroma being the most common (4 patients-1.3% of cases). Conclusion. Ovarian cancer treatment is planned individually, depending on the stage of the disease, histological tumor type, patient's general condition, wish for fertility-sparing treatment and technical capacity of the institution where the treatment is performed.

show abstract

Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary

Abstract: The prognosis for women with stage 1A/IC1 is very good. Surgical staging category was the only independent prognostic factor for RFS in stages IA/IC1 CCC.

Cited by 17 publications

References 22 publications

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

Age and Lymph Nodes Examination May Be Related to the Outcome of Ovarian Clear Cell Carcinoma: A SEER Analysis

Novel diagnostic and therapeutic approaches to the treatment of ovarian cancer

Contact Info

Product

Resources

About